# VB15010

Source: https://onco.cc/drugs/vb15010/  
OnCo record `vb15010` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VB15010 is an experimental pill targeting the PARP1 DNA-repair enzyme.

## Summary

NCT06819215 is a recruiting phase 1/2 study of VB15010 in advanced solid tumours. The registry describes PARP1 inhibition; there is no marketing approval or comparative clinical efficacy claim here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest; registry-only
- Code: VB15010
- Modality: Small-molecule inhibitor
- Mechanism: The registry describes VB15010 as a PARP1 inhibitor.

## Sources

- ClinicalTrials.gov: trials of VB15010: https://clinicaltrials.gov/search?intr=VB15010
- ClinicalTrials.gov NCT06819215: https://clinicaltrials.gov/study/NCT06819215

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06819215/)

---
JSON: https://onco.cc/api/v1/entities/vb15010.json